Phase II study of strepozotocin (NSC-85998) in the treatment of advanced gastrointestinal cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000188:drug therapy; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002276:Carcinoid Tumor / Q000188:drug therapy; D005260:Female; D005706:Gallbladder Neoplasms / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000188:drug therapy*; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011507:Proteinuria / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014508:Urea / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D001786:Blood Glucose; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea; D001663:Bilirubin